New and emerging treatments for metabolic dysfunction-associated steatohepatitis

Cell Metab. 2024 May 7;36(5):912-926. doi: 10.1016/j.cmet.2024.03.011. Epub 2024 Apr 11.


Metabolic dysfunction-associated steatohepatitis (MASH) is a leading etiology of chronic liver disease worldwide, with increasing incidence and prevalence in the setting of the obesity epidemic. MASH is also a leading indication for liver transplantation, given its associated risk of progression to end-stage liver disease. A key challenge in managing MASH is the lack of approved pharmacotherapy. In its absence, lifestyle interventions with a focus on healthy nutrition and regular physical activity have been the cornerstone of therapy. Real-world efficacy and sustainability of lifestyle interventions are low, however. Pharmacotherapy development for MASH is emerging with promising data from several agents with different mechanisms of action (MOAs) in phase 3 clinical trials. In this review, we highlight ongoing challenges and potential solutions in drug development for MASH and provide an overview of available data from emerging therapies across multiple MOAs.

Keywords: MASH; MASLD; NAFLD; NASH; fibrosis; non-invasive testing; pharmacotherapy; steatosis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Fatty Liver* / metabolism
  • Fatty Liver* / therapy
  • Humans
  • Metabolic Diseases / metabolism
  • Metabolic Diseases / therapy